+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating whether apixaban, an oral anticoagulant tablet, can reduce blood clots in people with lung cancer who are receiving chemotherapy or similar systemic anticancer treatments. Venous thromboembolism VTE is a common and serious complication in lung cancer patients undergoing such therapies, leading to poorer quality of life, higher healthcare costs, and increased morbidity and mortality. Current standard care does not routinely use blood thinners for outpatients receiving systemic anticancer therapy, and this trial aims to address that gap. Participants will be randomly assigned to receive either apixaban 2.5 mg tablets or a matching placebo, taken twice daily by mouth for six months alongside their cancer treatments. This phase 3, multicenter, double-blind, placebo-controlled trial will compare these two groups to assess if apixaban reduces the rate of VTE. The trial includes a total of 1456 patients recruited over 36 months with a follow-up period of 6 months for primary outcome measurement. During the trial, participants will be asked to take the study medication as directed and complete diaries recording treatment adherence. They will also complete quality of life and health resource use questionnaires. Researchers will monitor for blood clots confirmed by objective testing, bleeding events, survival outcomes, and patient-reported quality of life over six months. Female participants who can become pregnant are required to use effective contraception during and shortly after treatment. The studys total duration, including setup and analysis, is planned for 60 months.

Age: 16Years +All GendersPhase 3
8 locations
A

Actively Recruiting

Researchers are studying patients with breast cancer who have limited nodal disease confirmed by biopsy and are undergoing primary surgery. The study evaluates targeted sentinel node biopsy TSNB as a method to assess axillary lymph node involvement and compares its outcomes to other staging methods. This observational audit aims to collect data on surgical results, arm lymphoedema, and disease progression, benchmarking against previous trials and current guidelines. Participants will undergo TSNB where the marked, biopsy-proven positive node is removed along with sentinel nodes, following standard local practices and protocols such as those used in the ATNEC trial. The marked node may be identified using clips, dyes, magnetic seeds, or other techniques. At least three nodes should be removed for adequate assessment. Further axillary treatment decisions after TSNB will be made by the treating multidisciplinary team based on local protocols. During the study, participants will be followed for up to 60 months with regular assessments of nodal metastases, identification rates of marked nodes, false negative rates, and arm lymphoedema. Secondary outcomes include axillary, regional, and local recurrence, disease-free survival, and overall survival. Data collection will include histology results and clinical follow-up to monitor outcomes and treatment effectiveness in this patient population.

Age: 18Years +All Genders
14 locations
S

Actively Recruiting

Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.

Age: 18Years +All GendersPhase Not Applicable
98 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
I

Actively Recruiting

Researchers are evaluating the effects of lowering blood phosphate levels in adults with end-stage kidney disease ESKD who are receiving dialysis. This trial compares intensive lowering of serum phosphate towards the normal level 1.50 mmolL with a more liberal target 2.0 to 2.5 mmolL to see if it reduces death or major cardiovascular events, and improves physical health and quality of life. The study is a large, international, randomized controlled trial sponsored by The University of Queensland. Participants will be randomly assigned to one of two groups one targeting a liberal serum phosphate level where phosphate-lowering medications are only prescribed if levels exceed 2.5 mmolL, and the other aiming for an intensive target with medications used to lower phosphate to normal levels. The choice and dose of phosphate binders will be decided by the treating physician and participant. The treatment period is expected to last up to five years. During the study, participants will be monitored for cardiovascular events, death, physical health, fatigue, quality of life, and patient satisfaction. Assessments include tracking the time to cardiovascular death or major cardiovascular events, all-cause death, and quality of life using the EQ5D-5L measure. Data will be collected throughout the treatment period, with safety and effectiveness evaluated over five years.

Age: 18Years +All GendersPhase Not Applicable
126 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations
S

Actively Recruiting

Researchers are studying patients with newly diagnosed stage I, II, and III colorectal cancer CRC to understand how circulating tumor DNA ctDNA in the blood can predict disease relapse. The study evaluates whether using ctDNA to guide adjuvant chemotherapy decisions after surgery is as effective as standard chemotherapy, aiming to reduce unnecessary treatments and side effects. This multi-center, prospective research includes both observational and randomized components to better manage early-stage CRC. The study has two parts Part B focuses on collecting tumor tissue, serial blood samples, and clinical data to detect minimal residual disease MRD using ctDNA after curative surgery. Part C is a randomized trial comparing ctDNA-guided adjuvant chemotherapy versus standard care in patients with high-risk stage II or III CRC. Patients are randomized post-surgery to either standard chemotherapy or a ctDNA-guided approach where those testing negative for ctDNA may receive less chemotherapy. Participants will undergo regular blood sampling and clinical assessments to monitor ctDNA levels and disease status. Researchers will measure outcomes such as 3-year disease-free survival and the relationship between ctDNA detection and treatment response over several years. The study includes follow-up periods of 4 to 8 years to evaluate long-term outcomes and safety. Participants need to consent, adhere to follow-up schedules, and be suitable for chemotherapy if randomized to Part C.

Age: 18Years +All Genders
71 locations
A

Actively Recruiting

Idiopathic pulmonary fibrosis IPF is a progressive lung disease causing scarring that leads to coughing and breathlessness. Many IPF patients also have reflux disease, where stomach acid can damage the lungs. This research aims to find out if treating IPF patients with proton pump inhibitors PPIs, which reduce stomach acid, can slow down the progression of IPF. The trial is a randomized, placebo-controlled study involving 298 IPF patients across about 37 UK hospitals. Participants will be randomly assigned to take either lansoprazole a PPI or dummy tablets twice daily for 12 months. They will start weekly breathing tests at home using equipment provided and, if they have a cough, use a device to count coughs over 24 hours. Participants will complete questionnaires about coughing, breathlessness, sleep habits, and overall health. Some will also wear activity and sleep monitors during cough monitoring sessions. Dose reduction is allowed if side effects occur. During the study, patients will complete regular questionnaires and provide blood samples for safety checks at 3, 6, 9, and 12 months. Weekly home spirometry will continue for the full year. Researchers will track lung function, cough frequency and severity, breathlessness, quality of life, sleep quality, reflux symptoms, and hospital-free survival. Remote and in-person visits are possible, and participants will receive training on study procedures. The primary outcome is the change in lung function 12 months after starting treatment.

Age: 40Years +All GendersPhase 3
57 locations
I

Actively Recruiting

This research aims to compare two standard care approaches in very premature infants born before 30 weeks to see if withholding enteral feeds around the time of blood transfusion reduces the risk of Necrotizing Enterocolitis NEC, a serious intestinal disease. NEC can severely damage the bowel and has a high risk of death or long-term health problems. The study involves infants from neonatal intensive care units in Canada and the UK and evaluates if withholding or continuing feeds during transfusion affects outcomes. The study randomly assigns infants to one of two groups one where all enteral feeds are stopped for 4 hours before, during, and after packed red cell transfusion and another where feeding continues as usual throughout the transfusion period. Infants will remain on their assigned feeding strategy until reaching 34 weeks and 6 days gestational age. During feed withholding, hydration and blood sugar are maintained by parenteral nutrition or intravenous glucose according to local practice. Participants will be monitored from randomization until 40 weeks postmenstrual age for the development and severity of NEC, death, infections, nutritional support duration, growth, and other health outcomes. Researchers will track feeding practices, transfusions, and clinical events, with long-term follow-up until discharge from the hospital. The study intends to identify which feeding approach during transfusion might better prevent NEC in these vulnerable infants.

Age: 0 - 30WeeksAll GendersPhase Not Applicable
40 locations